Overall, our findings illustrate the importance of addressing small-molecule key features to guide the discovery of modulators of ERCC1–XPF interaction, providing important insights leading to the identification of potential inhibitors with novel chemotypes to be used in combination with cisplatin therapy in NSCLC. The gene discussed is ERCC4; the disease is non-small cell lung carcinoma.